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Summary The mapping of allelic loss on the short arm of chromosome 1 has been performed in non-small-cell lung cancer. We used a set
of 11 microsatellite loci spanning lp to examine the frequency of allelic imbalance in a panel of 58 tumours. Fifty-one of 58 (87.9%) cases
have shown somatic allelic loss at one or more loci tested. The two shortest regions of the overlap (SRO) of the deletions have been
identified: SRO 1 at 1p13.1 and SRO 2 at 1p32-pter. Allelic losses at these regions have been compared among adenocarcinoma and
squamous cell carcinoma and no difference has been found. In contrast to SRO 1, deletions at SRO 2 significantly correlated with advanced
stage of the disease as well as post-operative metastasizing and relapse. These data may suggest that SRO 1 and SRO 2 can harbour
tumour-supressor genes (TSGs) involved in different stages of NSCLC development. SRO 2 is still quite large and its refined mapping should
help attempts to clone and identify the putative TSG(s). Microsatellite instability (replication errors) affecting only 6 (10.3%) of 58 tumour
samples is an infrequent genetic alteration at the loci tested.
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Genomic alterations, occurring in non-small-cell lung cancer
(NSCLC), have been revealed in oncogenes and tumour-suppressor
genes (Carbone and Minna, 1992). The most important findings
concerning the last group are inactivation by deletions and/or point
mutations of p53 (Chiba et al, 1990), CDKN2/MTSl/pJ6INC4
(Washimi et al, 1995) and several regions on chromosome 3p
(Houle et al, 1991; Gray et al, 1995; Roche et al, 1996).
Furthermore, several regions on lp, lq, 2q, 5q, 8q, Ilp, 12p, 13q,
18q and 22q have been reported to be frequently affected by
recurrent loss ofgenetic material (Weston et al, 1989; Shiseki et al,
1994; Fong et al, 1995a; Takeuchi et al, 1996). It may imply the
presence of unknown tumour-suppressor genes of considerable
importance on these chromosomes.
Cytogenetic analysis ofNSCLC has shown aconsistent deletion
at lpl3 (Testa and Siegfried, 1992; Lukeis et al, 1993; Johansson
et al, 1994), although the use of cytogenetic analysis is compli-
cated for these tumours because of a low mitotic index and
extremely complex karyotypes with many additional chromo-
somes (Testa and Siegfried, 1992).
Restriction fragment length polymorphism (RFLP) analysis has
revealed allelic loss at lp32-35 in 14-18% of informative cases
(Tsuchiya et al, 1992; Sato et al, 1994; Shiseki et al, 1994).
However, RFLP markers are of limited use because of 50%
heterozygosity at any one locus (Hoggard et al, 1995).
Allelotyping using highly informative, well-distributed micro-
satellite markers may reveal more comprehensive data. For
example, Fong et al (1996) have recently shown allelic loss at Alu
VpA locus MYCLI (lp32) in 29% ofinformative NSCLCs.
Microsatellite sequences that are also disposed to instability
appeared as either a substantial change in repeat length (often
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heterogeneous in nature) or a minor change [for (CA)n repeats -
typically 2 bp] (Thibodeau et al, 1993). Microsatellite instability
(MI) has been identified as a novel genetic abnormality in tumours
of patients with hereditary non-polyposis colorectal cancer
syndrome (HNPCC) (Aaltonen et al, 1993; Thibodeau et al, 1993)
and has been also reported in sporadic types ofHNPCC-associated
tumours of the colon, pancreas and stomach (Han et al, 1993;
Peltomaki et al, 1993). Although HNPCC-unrelated sporadic
tumours of bladder, brain and lung have been shown to have a
much lower frequency of MI (Gonzalez-Zulueta et al, 1993;
Peltomaki et al, 1993; Fong et al, 1995b; Zhu et al, 1996), contro-
versial data forboth small-cell and non-small-cell lung carcinomas
have been published (Merlo et al, 1994; Shridhar et al, 1994).
To date, a few allelotyping studies of chromosome lp in
NSCLC have been performed, and the limited number ofloci have
been screened. The data about MI frequency for NSCLC are
conflicting, and studies of microsatellite loci spanning chromo-
some lp are of great interest. We performed allelotyping of 11
microsatellite loci spanning the short arm of chromosome 1 in
NSCLC patients with different clinicopathological parameters:
age, sex, histological type of tumour, rate of cell differentiation,
stage of disease, rate of relapse and metastatic manifestation after
surgical operation. The two shortest regions of the overlap (SRO)
ofthe deletions have been identified: SRO 1 at lpl3.1 and SRO 2
at lp32-pter. These regions may harbour tumour-supressor genes
involved in NSCLC development. Microsatellite instability has
been found infrequently at the loci tested.
MATERIALS AND METHODS
Specimen collection and nucleic acid extraction
Tumour tissue was obtained from 58 patients with non-small-cell
lung carcinoma, including 36 cases of squamous cell carcinoma
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Figure 1 Clinicopathological data and allelotyping of 1 p microsatellite loci in 58 non-small-cell lung carcinomas. aM, male; F, female. bHistological subtype;
SqC, squamous cell carcinoma; AC, adenocarcinoma; ASqC, adenosquamous carcinoma. cCell differentiation, Gi, well; G2, moderate; G3, low; GX not
identified. dWhite boxes, retention of heterozygosity; black boxes, LOH; hatched boxes, replication errors; grey boxes, not informative or not identified. Group A
(see the text), 1p32-pter, include case nos 7, 10, 12, 13, 16, 18, 21, 23, 27, 35, 40, 41, 54. Group B, 1p21-pcen, include case nos 1, 29, 30, 45, 46, 50, 53, 58.
Group C, both named above regions, include case nos 3, 14, 15, 17, 19, 20, 24, 25, 28, 31, 36, 37, 38, 42, 43, 44, 47, 48, 51, 55, 57
British Journal of Cancer (1998) 77(10), 1604-1611
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
0 Cancer Research Campaign 1998
I I
m I
0 1
I
I
m1606 AVGasparian etal
Table 1 Associations between loss of heterozygosity at SRO and clinicopathological parameters
Characteristic SRO 2 (1p32-pter) SRO 1 (lp 13.1)
LOH No Statistical LOH No LOH Statistical
LOH estimation estimation
Age
Mean age (years) 57.8±2.6 58.3±1.9 NS, 55.7±1.7 57.7±1.6 NS,
Student's test Student's test
Sex
Male 18 27 NS, 26 21 NS
(40.0%) (60.0%) Fisher's exact test (55.3%) (44.7%) Fisher's exact test
Female 2 5 3 5
Histological subtype
SqC 16 20 NS, 18 18 NS
(44.4%) (65.6%) Fisher's exact test (50.0%) (50.0%) Fisher's exact test
AC 3 10 8 7
(23.1%) (76.9%) (53.3%) (46.7)
ASqC 1 2 3 1
Nodal status
NO 5 20 P = 0.022, 16 10 NS
(20.0%) (80.0%) Fisher's exact test (61.5%) (38.5%) Fisher's exact test
N1-N3 15 13 13 16
(53.6%) (44.8%) (44.8%) (55.2%)
Tumour size
T1-T2 10 25 P= 0.067a, 19 17 NS
(28.6%) (71.4%) Fisher's exact test (52.8%) (47.2%) Fishers exact test
T3-T4 10 7 10 9
(58.8%) (41.2%) (52.6%) (47.4%)
Clinical stage
3 19 P= 0.002, 13 10 NS
(6.3%) (93.7%) Fisher's exact test (58.8%) (41.2%) Fisher's exact test
III-IV 17 13 18 14
(56.7%) (43.3%) (56.3) (43.7)
LOH, tumours with loss of heterozygosity; no
significance (0.05 < P< 0.1).
LOH, tumours that retained heterozygosity; NS, no statistical significance (P ,, 0.05); atrend towards statistical
(SqC), 16 cases ofadenocarcinoma (AC) and four adenosquamous
(mixed type) tumours (ASqC). All patients were treated from 1993
to 1995 at the Blokchin Cancer Research Centre, Moscow, Russia.
Immediately after surgery, the tumour samples were snap-frozen
in liquid nitrogen. As a source of normal DNA, we used lympho-
cytes of peripheral blood. None of the patients had received
chemotherapy or radiotherapy before surgery. Histological exami-
nation of the samples was realized according to 1982 WHO
criteria and stage of disease was assigned in accordance with the
International Union Against Cancer (1986). DNA was extracted
from tumour cells and lymphocytes using standard methods
(Sambrook et al, 1989).
PCR and allelotyping studies
The allelotyping study was performed using PCR amplification of
11 microsatellite repeat polymorphisms (CA repeats, DIS514,
DIS2881, DIS239, DIS236, DIS499, DIS417, DIS162, DIS247,
DIS160, DIS243 (Dib et al, 1996) and Alu VpA repeat, MYCLI
(Makela et al, 1992)). The map positions are summarized in Figure
3. Genomic DNA (100 ng) was amplified in a reaction mixture
(50 gl), containing 1.5 mm magnesium chloride, 50 mM potassium
chloride, 20 mm Tris-HCl (pH 8.4), 250 mm of each deoxy-
nucleotide triphosphate, 150 ng of each primer and 0.4 U Taq
polymerase (Perkin-Elmer/Cetus). PCR occurred after a 3-min
initial denaturation at 95°C, with 35 cycles of30 s each ofdenatu-
ration at 95°C, 30 s ofannealing at 55°C, and 45 s ofelongation at
72°C. This was followed by a final extension step of 10 min at
72°C. A 3-,ul sample of the PCR product was mixed with 6gl of
loading buffer, consisting of 0.025% bromophenol blue, 0.025%
xylencyanol FF and 97% formamide, denatured for 10 min at
100°C and immediately cooled in ice until electrophoresis. A 2-gl
sample of mixture was loaded onto a 6% sequencing polyacry-
lamide gel and run for6 h at 1780 V. Separated PCR products were
then dry transferred onto Hybond N+ membrane (Amersham) and
hybridized with (CA),, probe (for MYCLI - one of the PCR
primers), end-labelled with [,y-32P]dATP by T4 polynucleotide
kinase (Biolabs, US). Hybridization was carried out for 12 h at
42°C in a buffer containing phosphates (disodium hydrogen phos-
phate/sodium dihydrogen phosphate 0.13 M, sodium chloride 0.25
M, sodium dodecyl sulphate) (SDS) 7% and PEG 6000 10%.
Filters were washed at room temperature twice during 10 min in
buffer containing 0.1% SDS and 2 x standard saline citrate (SSC),
exposed to radiograph film (XBM, Germany) with an intensifying
screen at - 70°C during 12-24 h.
Microsatellite imbalance was assessed visually by two indepen-
dent observers. Cases that were difficult to interpret were analysed
using a densitometer. LOH was considered to occur when the
intensity ofthe allele in tumour DNA was approximately less than
50% ofthat in the corresponding normal DNA (Figure 2).
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Figure 2 Representative autoradiographs at tested lp loci in NSCLCs. PCR products from lymphocyte DNA are in the right lanes (L), from tumour DNA are in
the left lanes (T). Case no. 22, loci D1S243, D1S16O, MYCL1, D1S417, D1S499, D1S236, D1S239 and D1S2881 revealed loss of one allele in tumour DNA
(arrows), whereas D1S514 showed retention of both alleles. Case no. 6 examples of replication errors - formation of the new allele (D1S499), shift of
electrophoretic mobility at simple sequence tandem repeat (D1S243)
Statistical analysis
The two-tailed Fisher's exact test was used for comparative
analysis ofLOH frequency in analysed loci, as well as for the rela-
tionship between molecular and qualitative clinicopathological
characteristics. The age of patients in groups with and without
LOH at SROs was analysed using Student's test. Log-rank
analysis was performed (BMDP, survival program) to determine
the relationship between allelic loss at SROs and post-operating
metastasizing and relapse of tumour.
RESULTS
Paired tumour/normal DNA samples from 58 NSCLC patients
were examined for allelic imbalance for microsatellite loci at
the short arm ofchromosome 1. The results are shown in Figure 1.
Clinicopathological characteristics have been compared with the
allelic status ofpatients (Table 1).
Loss of heterozygosity
Allelic imbalance or loss of heterozygosity (LOH) (Figure 2)
occurred in at least one locus in 51 of 58 tumours (87.9%) (black
boxes in Figure 1). High levels of LOH frequency (>40%) were
found for seven loci (Figure 3): DIS514 (46.7%), DIS2881
(40.5%), DIS162 (40.9%), MYCLI (44.9%), DIS247 (44.8%),
DIS160 (50.0%) andDIS243 (41.9%). To analyse the differences in
LOH frequency between all possible combinations of loci, Fisher's
exact test was used. No differences were noted between loci
DJS514, DIS2881 (lpl3.1), D]S239 (lp21), DIS417 (lp3l.3-32),
DIS162, MYCLI (lp32), DIS247 (1lp34.3-35), DIS160 (lp36.2)
and DIS243 (lp36.3). However, a significant difference (P < 0.05)
or apparent trend towards significance (P < 0.1) in LOH frequency
has been observed between loci at lpl3.1, lp32-pter and loci
localized in the middle area of lp: DIS236 and DIS499.
To determine the shortest regions ofoverlap, the special approach
was used (Bieche et al, 1993). All cases ofallelic loss may be classi-
fied on the basis of their location. We have supposed the entire or
nearly entire (all informative loci were LOH affected with the
exception ofDlSS514) lp deletion in five cases only: nos 8, 9, 11, 22
and 26 (Figure 1). To take into account the absence of sufficient
information for several cases, 42 cases with partial deletions and
clear allelotype for most of the loci tested may be subdivided into
three groups: A - with deletions at the distal part of lp (n = 13); B -
with deletions at the proximal part of lp (n = 8); and C - tumours
with deletions atboth these regions (n =21). Forexample, in tumour
no 3 loci DIS514, D1S239 at the proximal part of Ip and four loci at
the distal part of lp had lost one allele, whereas interstitial loci -
DIS236, DIS499 remained heterozygous (see Figure 1). Thus, case
no 3 was included in group C. Alternatively, in cases no 7 and no 30,
LOH was determined at one of these regions only, and these cases
were included in groups A and B respectively. Analysis of groups B
and C allows us to define the SRO, which included DIS514-
DIS2881 (lpl3.1): 20 tumours had allelic loss at least at one of
these loci and ten tumours had LOH at both loci. On the other hand,
in groups A and C most tumours reveal a pattern ofLOH consistent
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Figure 3 Idiogram of chromosome 1p with results on LOH at microsatellite
loci tested
with distal deletion ofthe short arm ofchromosome 1. The shortest
region of overlap, included in deletions of 15 tumours, appeared
between DIS162 and DIS243. Thus, we have defined the two
shortest regions of overlap, mapped at lpl3.1 (SRO 1) and at
1p32-pter (SRO 2) (Figures 1 and 3).
We also analysed the relationship between LOH for both SROs
and traditional clinicopathological parameters: age, sex, histolog-
ical type, rate ofcell differentiation and TNM classification (Table
1). No significant difference has been observed in LOH frequency
between adenocarcinoma and squamous cell carcinoma. On the
other hand, LOH at SRO 2 has been significantly associated with
biological evidence of tumour progression: lymph node involve-
ment was found in 15 of20 tumours with LOH, compared with 13
out of 33 cases without LOH (P = 0.022) (Table 1). An apparent
trend towards significance has been demonstrated between LOH at
SRO 2 and tumours with the classification T3-T4 (P = 0.067).
Finally, stage III-IV tumours have been affected more frequently
at these regions than tumours from patients with stage I-II of
disease (17 out of 30 vs 3 out of22, P = 0.002). The same correla-
tion has not been found for SRO 1.
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Figure 4 Progression of disease after surgery in relation to deletions at
SROs
The association between LOH at SRO and progression of
disease after surgical treatment was also analysed using the log-
rank test. The further development of disease in 37 patients was
tracked not less than 2 years afteroperation. To analyse the associ-
ation with respect to SRO 2, these patients were subdivided into
two groups: those with big deletions involving lp32-36 (n = 17);
and those with LOH at more proximal loci only (n = 20, Figure 4).
As SRO 1 is not big, 19 cases with LOH at DIS514 and/or
DIS2881 only vs 17 cases with LOH at more distal loci were
analysed with regard to tumour progression. Patients with LOH at
SRO 2 had a more frequent post-operating metastatic manifesta-
tion and relapse than those without LOH (n = 20; X2 = 5.146,
P = 0.023). We did not have the same association for SRO 1
(%2 = 0.831, P = 0.362). Thus, in contrast with SRO 2, deletions at
SRO 1 have not been associated with advanced stage ofdisease.
Microsatellite instability
Six (10.3%) of58 tumour samples have been detected that harbour
MI in at least one locus (hatched boxes in the Table 1). This
phenomenon appeared as either formation ofthe new allele or shifts
of electrophoretic mobility at simple sequence tandem repeat loci
(Figure 2). MI was present at eight of the loci tested but not at
DIS417, MYCLI and DIS247. MI was detected atDIS162 in three
tumours, atD1S499 in two tumours and at other affected loci in one
tumour. Fourofthe six patients with MI had lymph node metastasis
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at the time ofsurgical intervention and one of six patients had stage
I disease (P = 0.081). One patient (no. 6) harboured different types
of MI at multiple loci (Figure 1). Previously, we detected a mutant
KRAS gene (codon 12) in case no. 6 out of 30 analysed
(Yakubovskaya et al, 1995). The findings indicate high genetic
instability ofthis tumour. It must be stressed that tumour no. 6 was
10 x 10 x 12 cm and clinical classification T4N3MO.
DISCUSSION
Microsatellite markers are successfully used in allelotyping
studies for the search of unknown TSGs that are involved in
NSCLC development. Allelic losses at single loci on chromosome
lp have been described (Tsuchiya et al, 1992; Sato et al, 1994;
Fong et al, 1996). In the present study, we have tried to perform
detailed deletion mapping using 11 microsatellite loci spanning 1p
in an effort to identify the SRO of the deletions where specific
TSG(s) may reside.
Our results indicate allelic imbalance at all of the loci tested.
The terms 'allelic imbalance', 'loss of heterozygosity' and 'allele-
specific deletions' are used equally because cytogenetic studies
have rarely shown lp amplification in NSCLC, whereas deletions
have been found (Testa and Siegfried, 1992; Lukeis et al, 1993).
Furthermore, gene LMYC (lp32) is rarely amplified (< 1%) in
these tumours (Yokota et al? 1988).
We identified the two SRO ofthe deletions: SRO 1 between loci
DJS514 and DIS2881 (lpll3.1), and SRO 2 between DIS162 and
DIS243 (lp32-pter).
Previously in NSCLC, two loci on lp were tested using the
RFLP technique: DIS57 (lp32-35) and MYCLI (last marker
shapes by the EcoRI restriction site inside the proto-oncogene)
(lp32). Sato et al (1994) and Tsuchiya et al (1992) reported LOH at
DIS57 in 15-18% of informative cases. Although LOH at MYCLI
was not shown in the initial study by Kawashima et al (1988),
Shiseki et al (1994) have since described this alteration in 14% of
NSCLCs. A recent study ofAlu VpA locus MYCLI, mapped 16 kb
upstream of gene LMYC (Makela et al, 1992), showed allelic loss
in 29% of informative cases (Fong et al, 1996). We have found
more frequent LOH at this locus (40%). The discrepancies
observed may be the result ofrelatively small numbers ofinforma-
tive cases in RFLP study and different numbers of patients with
early and advanced stage in current and previous studies. Both
these possibilities are probably because only 18-22 informative
tumours were analysed in RFLP studies ofMYCLI (Kawashima et
al, 1988; Tsuchiya et al, 1992). On the other hand, a close correla-
tion was shown between LOH at Alu VpA locus MYCLI and
advanced stage of disease (Fong et al, 1996). In the present study,
30% of patients had early stage disease, whereas in two previous
reports patients with this stage from 50-55% of analysed groups.
Unfortunately, the impact of previous reports is limited because
only a single locus was tested in each study.
Using several loci, we observed that a common deleted region is
lp32-pter. Furthermore, LOH at SRO 2 correlates significantly
with advanced TNM stage and post-operating progression of
disease. These findings suggest that one or more crucial genes at
this region may be involved in NSCLC progression. It is known
that LMYC, JUN, BLYM, LCK and FGR oncogenes are located at
SRO 2. Allele-specific deletion is not considered obligatory for
direct oncogene activation. However, any deregulation (both up
and down) of LMYC expression, for example, may be crucial for
cell proliferation and differentiation (Hesketh, 1995).
On the other hand, LOH on the distal part of chromosome lp
has also been described in neuroblastoma (Fong et al, 1989;
Martinsson et al, 1995), malignant meningioma (Simon et al,
1995), multiple endocrine neoplasia type 2 (Moley et al, 1992) and
cancers of the liver (Kraus et al, 1996), kidney (Schwerdtle et al,
1996), colon (Leister et al, 1990), pancreas (Ding et al, 1992) and
breast (Bieche et al, 1993; Hoggard et al, 1995). Correlation with
the distal lp deletions in these cancers suggests that region
lp32-pter harbours TSG(s) that may be involved in development
ofmore than one tumour type. It is ofinterest that allelic loss atthe
distal part of chromosome 4 in mouse lung tumours localize a
putative TSG to a region homologous with human chromosome
lp34-pter (Herzog et al, 1995). To date, in this region candidate
TSGs include the CDK6 inhibitorp18 at lp32 (Guan et al, 1994)
and the protein kinase gene complex PITSLRE at lp36 (Lanti et al,
1994). Recently a new gene (p73) has been identified at the lp36
chromosomal region. This gene encodes a protein with significant
amino acid similarity to thep53 tumour suppressor gene (Kaghad
et al, 1997). Moreover, p73 can activate the transcription ofp53-
responsive genes and inhibit cell growth in a p53-like manner by
including apoptosis (programmed cell death) (Jost et al, 1997).
Possibly, the association between LOH at SRO 2 and poor prog-
nosis ofdisease is due top73 inactivation.
The SRO 2 is still quite large (on the other of 80 cM, see Figure
3), thus SRO 2 needs more precise deletion mapping. A test of
deletions in SRO 2 may be useful in making individual disease
development forecasts and it also may be used in complexes with
already known molecular markers of non-small-cell lung cancer
progression (Zborovskaya et al, 1996).
Cytogenetic analysis has shown frequent structural rearrange-
ments at lpl3 (Testa and Siegfried, 1992; Lukeis et al, 1993;
Johansson et al, 1994). Balanced translocations seemed to be rela-
tively rare in NSCLC. In contrast, deletions and derivative chro-
mosomes were often observed (Testa and Siegfried, 1992). Using
the molecular approach, we have found frequent allelic loss at
lpl3.1 (SRO 1). Deletions at the same region were found in breast
cancer (Bieche et al, 1993). Oncogene NRAS is localized at lpl3.
There are no data about its disregulation in NSCLC; however,
structure and functional peculiarities ofthe remaining alleles have
not been examined. According to our results, there is no associa-
tion between LOH at this region, clinicopathological parameters
and post-operating progression of disease. These results, however,
are not contrary to the possibility that inactivation of putative
TSG(s) may be involved in the early steps oftumour development.
In this study, MI was found in six cases (10.3%). Our results
support two previous studies that showed low frequency of MI in
NSCLC (2-6.5%) (Peltomaki et al, 1993; Fong et al, 1995b). On
the other hand, it differs from data by Shridhar et al (1994), indi-
cating MI for 34% tumour samples (mainly loci, mapped on 3p).
This contradiction could be explained by the fact that various
chromosomes were analysed in contrasting studies and different
susceptibility of tested loci to MI may take place. It must be noted
that there is an epidemiological and inheriting heterogeneity of
analysed groups in different populations (Takagi et al, 1996).
We have observed a trend towards a relationship between MI
and advanced stage of disease. Although in hereditary tumours MI
caused aberrations in mismatch repair genes such as the hMSH2
gene (Fishel et al, 1993), for sporadic tumours the same associa-
tion has not been always found (Zhu et al, 1996). As far as MI is a
form of whole genetic instability, this correlation with advanced
stage of disease is not surprising.
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In conclusion, the study showed LOH at the regions Ipi3.1 and
lp32-pter in nearly 50% of the tested NSCLCs and may suggest
the location of possible tumour-suppressor genes of considerable
importance in these regions. The last region has been identified
with adverse clinical features by association of LOH. Refined
mapping ofthese regions and cloning ofthe target gene(s) will be
the next critical steps in the understanding ofthe biological impor-
tance of lp LOH in NSCLC development.
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